Nieves Martínez Lago, Specialist in the Field of Medical Oncology at University Hospital Complex of Santiago de Compostela, shared on X:
“Presidential, ARTEMIS-011
122 patients | R/R osteosarcoma
Ris-Rez (B7-H3 ADC) vs gemcitabine/docetaxel
- mPFS: 5.5 vs 1.4 mo (HR 0.33)
- ORR: 15% vs 2%
- DCR: 76% vs 33%
- OS immature (HR 0.51)
G≥3 TRAEs: 93% vs 83%
Promising new strategy!”
You can also read: ARTEMIS-011 at ESMO 2026: Risvutatug Rezetecan Significantly Improves PFS in Relapsed or Refractory Osteosarcoma
